Ligand director has 115 shares withheld for taxes

Ligand Pharmaceuticals Inc. director Martine Zimmermann had 115 shares withheld by the issuer on September 22, 2026, to pay tax liability arising from restricted stock unit settlement.

Rhea-AI Filing Summary

Ligand Pharmaceuticals Inc. director Martine Zimmermann had 115 shares withheld by the issuer on September 22, 2026, to pay tax liability arising from restricted stock unit settlement. The reported price was $298.50 per share, and Zimmermann’s direct holdings after the transaction were 3,782 shares. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Tax Withholding: 115 shares

Tax Withholding 1 txn

Insider Zimmermann Martine

Role Director

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock F1	115	$298.50	$34K

Holdings After Transaction: Common Stock — 3,782 shares (Direct)

Footnotes (1)

1. F1. Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units.

Key Figures

Shares withheld: 115 shares Reported price per share: $298.50 per share Direct holdings after transaction: 3,782 shares

3 metrics

Shares withheld 115 shares September 22, 2026; for tax liability arising from restricted stock unit settlement

Reported price per share $298.50 per share September 22, 2026 transaction

Direct holdings after transaction 3,782 shares After the September 22, 2026 transaction

Key Terms

restricted stock units, tax liability, shares withheld

3 terms

restricted stock units financial

"settlement of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax liability financial

"in payment of the tax liability"

shares withheld technical

"shares withheld by the Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many LGND shares did director Martine Zimmermann have withheld, and at what price?

On September 22, 2026, 115 shares were withheld by the issuer at a reported price of $298.50 per share to pay tax liability arising from restricted stock unit settlement. Zimmermann’s direct holdings after the transaction were 3,782 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/24/2026 - 05:22 PM Accepted by SEC EDGAR 09/24/2026 - 05:22 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zimmermann Martine

(Last) (First) (Middle)

555 HERITAGE DRIVE

SUITE 200

(Street)

JUPITER FLORIDA 33458

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LIGAND PHARMACEUTICALS INC [ LGND ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/22/2026		F		115(1)	D	$298.5	3,782	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units.

	By: /s/Andrew Reardon, Attorney-in-Fact For: Martine Zimmerman	09/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)